<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654053</url>
  </required_header>
  <id_info>
    <org_study_id>GAST-010-19F</org_study_id>
    <secondary_id>VOCAL-001</secondary_id>
    <nct_id>NCT03654053</nct_id>
  </id_info>
  <brief_title>Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis</brief_title>
  <acronym>SACRED</acronym>
  <official_title>Effect of Simvastatin on Hepatic Decompensation and Death in Subjects With High-risk Compensated Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III, randomized, double-blind, placebo-controlled, multi-center study seeks to&#xD;
      test whether simvastatin, a statin usually used to lower cholesterol to prevent heart&#xD;
      problems and strokes, can lower the risk of hepatic decompensation (developing symptoms of&#xD;
      cirrhosis) in U.S. Veterans who have compensated cirrhosis (the liver is scarred and damaged&#xD;
      but there are no symptoms). The study will also explore how changes or differences in genes&#xD;
      effect the safety and effectiveness of using statins and how the use of statins affects&#xD;
      quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HMG-coA reductase inhibitors (statins), independent of cholesterol-lowering effects, are&#xD;
      beneficial in liver diseases by reducing endothelial dysfunction, intrahepatic&#xD;
      vasoconstriction, inflammation and fibrosis, and can reduce portal vein blood pressure.&#xD;
      Clinically significant portal hypertension (hepatic vein wedge pressure greater than or equal&#xD;
      to 10mmHg) is the most important predictor of decompensation and death in patients with&#xD;
      cirrhosis.&#xD;
&#xD;
      This randomized, double-blind, placebo-controlled, multi-center Phase III interventional&#xD;
      study seeks to demonstrate that statin therapy in patients with cirrhosis at high-risk for&#xD;
      hepatic decompensation will reduce the incidence of hepatic decompensation, hepatocellular&#xD;
      carcinoma or all-cause mortality.&#xD;
&#xD;
      Patients with compensated cirrhosis at high-risk for hepatic decompensation will be&#xD;
      stratified based on the presence or absence of varices and randomized to simvastatin 40mg/day&#xD;
      for up to 24 months. Patients will be observed for the development of hepatic decompensation&#xD;
      (variceal hemorrhage, ascites, encephalopathy), hepatocellular carcinoma, liver-related&#xD;
      death, death from any cause, and/or complications of statin therapy. Additionally, the&#xD;
      interaction of SLCO1B1 and KIF6 polymorphisms on safety and clinical efficacy of statin&#xD;
      therapy and the impact of statin exposure on health-related quality of life in patients with&#xD;
      compensated cirrhosis will be examined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Survival free from hepatic decompensation</measure>
    <time_frame>24 months</time_frame>
    <description>Occurrence of hepatic decompensation measured by first variceal hemorrhage, or development of ascites, or onset of hepatic encephalopathy, or hepatocellular carcinoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver-related death</measure>
    <time_frame>24 months</time_frame>
    <description>Occurrence of death after hepatic decompensation, or hepatocellular carcinoma or transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free from major cardiac events</measure>
    <time_frame>24 months</time_frame>
    <description>Occurrence of acute myocardial infarction, or unstable angina, or acute ischemic stroke, or coronary revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient health-related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Clinically significant change in score from baseline to month 12 as assessed by the PROMIS-29 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statin-related hepatotoxicity</measure>
    <time_frame>24 months</time_frame>
    <description>Occurrence of hepatotoxicity defined as Grade 3 liver toxicity per CTCAE 5.0 ( 5 times upper limit of normal as defined by local laboratory- transaminases)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myositis</measure>
    <time_frame>24 months</time_frame>
    <description>Occurrence of myositis defined as either Grade 3 myositis (pain associated with severe weakness; limiting self care Activities Daily Living {ADL}) OR Grade 4 creatine phosphokinase by CTCAE 5.0 ( 10x upper limit of normal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhabdomyolysis</measure>
    <time_frame>24 months</time_frame>
    <description>Occurrence of rhabdomyolysis defined as Grade 3 (symptomatic, urgent intervention indicated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatotoxicity</measure>
    <time_frame>24 months</time_frame>
    <description>Liver enzyme testing (AST, ALT, alkaline phosphatase, total bilirubin) at each study visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo taken once nightly at bed time.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 40mg</intervention_name>
    <description>Simvastatin 40mg taken once nightly at bed time.</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Simvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  U.S. Veteran&#xD;
&#xD;
          -  Cirrhosis due to chronic viral hepatitis, or alcohol or non-alcoholic fatty liver&#xD;
&#xD;
          -  Compensated cirrhosis (history of endoscopically-confirmed variceal hemorrhage,&#xD;
             absence of overt ascites, history of overt non-precipitated encephalopathy)&#xD;
&#xD;
          -  Age &gt; 18 and &lt;= 80&#xD;
&#xD;
          -  High risk of cirrhosis decompensation as defined by any of the following:&#xD;
&#xD;
               -  Presence of esophageal varices on endoscopy&#xD;
&#xD;
               -  Presence of portosystemic collaterals on imaging as determined by a body&#xD;
                  radiologist&#xD;
&#xD;
               -  Fibroscan VCTE &gt;= 25kPa&#xD;
&#xD;
               -  Platelet count &lt;= 110 K/mm&#xD;
&#xD;
               -  44 total points (~50% of clinically significant portal hypertension using the&#xD;
                  ANTICIPATE Nomogram)&#xD;
&#xD;
          -  Competent to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to any statin within 2 years&#xD;
&#xD;
          -  Prior allergy or sensitivity to simvastatin&#xD;
&#xD;
          -  History of variceal hemorrhage confirmed endoscopically within the previous 2 years&#xD;
&#xD;
          -  Presence of overt ascites or treatment with diuretics for ascites&#xD;
&#xD;
          -  History of chronic, recurrent or episodic overt hepatic encephalopathy with asterixis&#xD;
&#xD;
          -  History of hepatocellular carcinoma&#xD;
&#xD;
          -  Child-Turcotte-Pugh C Stage (CTP Score &gt; 9)&#xD;
&#xD;
          -  Prior receipt of organ transplant&#xD;
&#xD;
          -  Participation in another pharmacological clinical trial within 3 months of the current&#xD;
             study&#xD;
&#xD;
          -  Pregnancy or anticipated pregnancy within 2 years&#xD;
&#xD;
          -  Breast Feeding&#xD;
&#xD;
          -  Patients with life expectancy &lt; 3 years due to comorbid conditions&#xD;
&#xD;
          -  Independent indication for initiation of statin therapy&#xD;
&#xD;
          -  Patients with any form of clinical atherosclerotic cardiovascular disease (ASCVD)&#xD;
&#xD;
          -  Patients with primary LDL-C &lt; 190 mg/dl&#xD;
&#xD;
          -  Patients with diabetes mellitus, age 40-75 years, with LDL-C levels of 70-189 mg/dl&#xD;
&#xD;
          -  Patients without diabetes, age 40-75 years, with an estimated 10-year ASCVD risk &lt; 16%&#xD;
&#xD;
          -  Need for concomitant administration of potent inhibitors of CYP34A4 enzymes&#xD;
             (medications or other supplements that should not be taken with simvastatin, including&#xD;
             cyclosporine, danazol, gemfibrozil, fenofibrate, extended release niacin,&#xD;
             itraconazole, ketoconazole, voriconazole, HIV protease inhibitors, boceprevir,&#xD;
             telaprevir, macrolide antibiotics - erythromycin, clarithromycin, telithromycin,&#xD;
             nefazadone, verapamil, diltiazem, dronedarone, amiodarone, renolazine, lomitapide, and&#xD;
             cobicistat)&#xD;
&#xD;
          -  Prior TIPSS shunt&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E. Kaplan, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajni L Mehta, MPH</last_name>
    <phone>(203) 668-5760</phone>
    <phone_ext>2228</phone_ext>
    <email>rajni.mehta@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David E Kaplan, MD MSc</last_name>
    <phone>(215) 823-5800</phone>
    <email>David.Kaplan2@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Francisco VA Medical Center, San Francisco, CA</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Monto, MD</last_name>
      <phone>415-221-4810</phone>
      <phone_ext>2958</phone_ext>
      <email>alexander.monto@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Christina Haight</last_name>
      <phone>4157502150</phone>
      <email>Christina.Haight@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar H Taddei, MD</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>2206</phone_ext>
      <email>tamar.taddei@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Rajni Mehta, BS</last_name>
      <phone>2036685760</phone>
      <email>rajni.mehta@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyorgy Baffy, MD</last_name>
      <phone>857-364-4327</phone>
      <email>gyorgy.baffy@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Yunren Bolortuya</last_name>
      <phone>8573646501</phone>
      <email>Yunren.Bolortuya@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center, Kansas City, MO</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>James J. Peters VA Medical Center, Bronx, NY</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristel Hunt, MD</last_name>
      <phone>718-584-9000</phone>
      <phone_ext>3600</phone_ext>
      <email>kristel.hunt@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Annabelle Perez</last_name>
      <phone>7185849000</phone>
      <phone_ext>6627</phone_ext>
      <email>Guerry.Perez@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayse Aytman, MD</last_name>
      <phone>718-836-6600</phone>
      <phone_ext>3716</phone_ext>
      <email>ayse.aytaman@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Yudkevich</last_name>
      <phone>7188366600</phone>
      <phone_ext>4719</phone_ext>
      <email>Jennifer.Yudkevich@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar H Taddei, MD</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>5335</phone_ext>
      <email>tamar.taddei@va.gov</email>
    </contact>
    <investigator>
      <last_name>David E. Kaplan, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Philadelphia MultiService Center, Philadelphia, PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David E Kaplan, MD</last_name>
      <phone>215-823-5800</phone>
      <phone_ext>206729</phone_ext>
      <email>david.kaplan2@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Burdzy</last_name>
      <phone>2154709960</phone>
      <email>alexander.burdzy@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center, Houston, TX</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben Hernaez, MD</last_name>
      <phone>713-791-1414</phone>
      <phone_ext>25152</phone_ext>
      <email>ruben.hernaez@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Aisha Khan</last_name>
      <phone>7134404670</phone>
      <email>Aisha.Khan@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center, Richmond, VA</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmohan Bajaj, MD</last_name>
      <phone>804-675-5802</phone>
      <email>jasmohan.bajaj@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Donna McMillion</last_name>
      <phone>8046755000</phone>
      <phone_ext>4330</phone_ext>
      <email>Donna.McMillion2@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System Seattle Division, Seattle, WA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Ioannou, MD</last_name>
      <phone>206-277-3136</phone>
      <email>george.ioannou@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>LYnn Edmondson</last_name>
      <phone>2062773597</phone>
      <email>Lynn.Edmondson@va.gov</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>hepatic decompensation</keyword>
  <keyword>HMG-coA reductase</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>clinical trial</keyword>
  <keyword>Human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

